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Alteration of DNA integrity is a potential cause of cancer
and it is assumed that reduced DNA repair capacity and
accumulation of DNA damage may represent intermediate
markers in carcinogenesis. In this case-control study, DNA
damage and nucleotide excision repair capacity (NER-
DRC) were assessed in association with sporadic colorectal
cancer (CRC). Both parameters were quantified by comet
assay in blood cells of 70 untreated incident patients and 70
age-matched healthy controls. mRNA expression and
polymorphisms in relevant NER genes were concurrently
analyzed. The aim of this study was to characterize
incident CRC patients for NER-DRC and to clarify
possible relations between investigated variables. Comet
assay and mRNA expression analysis showed that CRC
patients differ in repair capacity as compared to controls.
Patients had a lower NER-DRC and simultaneously they
exhibited higher endogenous DNA damage (for both P <
0.001). Accumulation of DNA damage and decreasing
NER-DRC behaved as independent modulating parame-
ters strongly associated with CRC. Expression levels of 6
out of 9 studied genes differed between groups (P £ 0.001),
but none of them was related to DRC or to any of the
studied NER polymorphisms. However, in patients only,
XPC Ala499Val modulated expression levels of XPC, XPB
and XPD gene, whereas XPC Lys939Gln was associated
with XPA expression level in controls (for all P < 0.05). This
study provides evidence on altered DRC and DNA damage
levels in sporadic CRC and proposes the relevance of the
NER pathway in this malignancy. Further, alterations in
a complex multigene process like DNA repair may
be better characterized by functional quantification of
repair capacity than by quantification of individual genes
transcripts or gene variants alone.
Introduction
Colorectal neoplasia is the third most common cancer
worldwide and the fourth leading cause of cancer death (1).
Recently, decreasing colorectal cancer (CRC) mortality rates
have been recorded in developed countries, most likely due to
larger efforts in cancer screening and/or improved treatment
(2). Since an early diagnosis of CRC is associated with
substantially better prognosis and curability, early biomarkers
and intermediary end points are called for to dissect the
complex process of colorectal carcinogenesis (3).
While in the etiopathogenesis of inherited CRC forms the
influence of particular genetic features prevails, sporadic forms
(around 80% of all cases) show a multifactorial pattern and are
determined by an interplay of multiple genetic and environmen-
tal/lifestyle factors (4). Well-established risk factors for sporadic
CRC are obesity, diet low in vegetables/fruits and rich in meat,
physical inactivity and smoking (5,6). Concurrently, the specific
nature of colon epithelium, which is a dynamically changing
system, makes it prone to genotoxic attacks of external source
and/or spontaneous genetic changes. The above reasons
underline the importance of efficient DNA repair machinery to
maintain the cellular genomic integrity. Indeed, well-supported
associations exist between DNA repair insufficiency and
inherited forms of CRC: hereditary nonpolyposis CRC is caused
by deficient mismatch repair and MUTYH-associated polyposis
is associated with deficient mutation in the base excision repair
(BER) gene MutY (7).
In sporadic CRC, there is no single germ-line mutation
causing a strong deficiency in DNA repair activity. However,
alterations of the individual DNA repair capacity (DRC) may
significantly modulate the susceptibility to this cancer, especially
in the context of gene–environment interactions. Family-based
studies have suggested that DRC is a phenotype with a strong
genetic basis, estimating heritability in the range of 48–75% (8).
DNA repair may be further modulated by environmental/lifestyle
factors via several possible mechanisms, such as activation/
inhibition of repair enzymes, different provision of building
blocks (nucleotides) for the repair machinery or regulation of
repair gene expression (9). Thus, DRC, comprising the effect of
both hereditary components and variable environmental factors,
characterizes the actual phenotype of the cells. Due to the above
aspects, estimation of DRC is naturally becoming a representative
biomarker and an integral part of modern molecular epidemio-
logical studies on cancer.
Nucleotide excision DNA repair (NER), one of the major
players in maintaining genomic integrity, may modulate
predisposition to various cancers as well as response to sub-
sequent treatment (10). So far, reduced NER-DRC was
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associated with several types of sporadic malignancies (summa-
rized in Table I). However, there is a lack of data on NER-DRC
in association with sporadic CRC. Additionally, the characteri-
zation of individual DNA repair profiles may be of further
importance for the implementation of targeted therapies. For
instance, platinum-based compounds are first-line cytostatic
drugs employed in CRC treatment and variability in NER
pathway has been linked to the different sensitivity towards
above chemotherapeutics (26,27).
Based on the above considerations, we have focused this
case-control study on evaluating NER-DRC and endogenous
DNA damage in peripheral blood mononuclear cells (PBMC)
from 70 newly diagnosed CRC patients and 70 healthy age-
matched controls from the Czech Republic. In this country,
CRC constitutes a serious health problem as it has among the
highest rates of incidence and mortality worldwide (28).
Simultaneously, we have also profiled mRNA expression
levels of nine genes involved in the incision phase of NER,
whose rate is measured by our functional assay. Further, we
have genotyped common single nucleotide polymorphisms
(SNPs) in four NER genes. Additionally, the above variables
were also analyzed in the context of individual biological and
lifestyle factors and principal clinical characteristics.
The strength of our approach was that we included in the
study only patients with newly diagnosed, histologically
confirmed sporadic CRC. The homogeneity of the study group
was further potentiated by the fact that all patients were sampled
prior to any surgical intervention or therapy, thus eliminating the
effects of these factors on the individual level of investigated
parameters and minimizing the bias on the results.
Materials and methods
Study population
The study population comprised 70 patients with sporadic CRC and 70 healthy
controls frequency matched for age. All participants were of Caucasian origin.
Incident cases were recruited at the time of the diagnosis among patients
visiting two surgical departments (Thomayer Teaching Hospital in Prague and
Teaching Hospital and Medical School in Pilsen, Czech Republic) between
2008 and 2010. Only new histologically confirmed CRC cases who did not
receive any surgery or other specific treatment prior to sampling were included
into the study. Collaborating clinicians provided clinical and pathological
characteristics for each CRC patient: presence of inflammatory processes,
number of polyps at colonoscopy, tumor localization, stage of the malignancy
[tumor, nodes, metastases staging system (TNM) according to Union of
International Cancer Control] and microsatellite instability (MSI) status.
Controls were selected from healthy individuals of similar age distribution
who provided blood samples voluntarily. Only subjects with no previous
diagnosis and without manifestation of any disease were included into the study.
Controls have not been exposed to any potentially harmful chemicals except for
those from environmental sources. No other selection criteria have been applied.
Participating subjects were properly informed about the aim of the research;
they signed a written consent and the approval for genetic analysis, in accord
with the Helsinki declaration. The Ethics Committees of the Thomayer
Teaching Hospital in Prague and Teaching Hospital and Medical School in
Pilsen (Czech Republic) approved the design of the study. Trained personnel
Table I. Reduced NER capacity detected in blood cells of patients with various types of sporadic cancer—an overview of the literature
Cancer Cases Controls Damage-inducing
agent
Assay References
Bladder 106 incident cancer,
previously untreated
137 matched by age,
sex and ethnicity
BPDE Comet assay Schabath et al. (11)





BPDE HCR Shi et al. (13)
Colorectal 40 sporadic CRC
28 hereditary predisposition
to CRC
39 not specified N-AcO-2-FAA UDS Pero et al. (14)
Cutaneous melanoma 312 newly diagnosed,
previously untreated
324 matched by age,
sex and ethnicity
UV HCR Wei et al. (15)
Head and neck 55 newly diagnosed,
previously untreated
61 matched by age, sex,
ethnicity and smoking status
BPDE HCR Cheng et al. (16)
123 newly diagnosed,
previously untreated
136 matched by age and sex BPDE Comet assay Xiong et al. (17)
744 newly diagnosed,
previously untreated
753 matched by age, sex
and ethnicity
BPDE HCR Wang et al. (18)
Non-melanoma skin 88 primary cancer 135 matched by sex and
age
UV HCR Wei et al. (19)
255 newly diagnosed,
previously untreated
333 unmatched UV HCR Wang et al. (20)
Non-small cell lung 316 newly diagnosed 316 matched by age, sex,
and smoking status
BPDE HCR Wei et al. (21)
467 newly diagnosed,
previously untreated
488 matched by age, sex,
ethnicity and smoking status
BPDE HCR Shen et al. (22)
108 with second primary cancer 99 matched by age and sex BPDE Comet assay Orlow et al. (23)
271 lung carcinoma patients 271 matched by age and smoking BPDE HCR Deng et al. (24)
Prostate 75 newly diagnosed,
previously untreated
96 matched by age and race UV HCR Hu et al. (25)
and 65 prevalent cancer
UV, ultraviolet light; HCR, host-cell reactivation assay; N-AcO-2-FAA, N-acetoxy-N-2-fluorenylacetamide; UDS, unscheduled DNA synthesis.











interviewed patients and controls, using a structured questionnaire. Study
subjects provided information on their lifestyle habits, body mass index (BMI),
diabetes and family/personal history of cancer (Table II). Lifelong or long-term
(at least six consecutive months) drug use or exposures to genotoxins were also
investigated by the questionnaire.
Isolation of PBMC
Eight milliliters of peripheral venous blood were drawn from each subject into
heparinized tubes, mixed 1:1 with RPMI 1640 medium (HEPES modification,
containing 2 mM L-glutamine, 10% heat-inactivated fetal bovine serum, 1.5%
phytohemagglutinin and 0.2% penicillin/streptomycin, Sigma-Aldrich), layered
over Histopaque-1077 (Sigma-Aldrich) and centrifuged at 320g for 40 min at
room temperature (RT). Isolated PBMC were counted and their viability was
checked by trypan blue exclusion. When viability was higher than 95%, cells
were aliquoted into cultivation tubes with medium (105 cells per 5-ml
medium). Tubes were incubated at 37C. After a mitogen-stimulation period of
20 h, PBMC were further processed for the challenge assay.
Challenge assay for evaluating NER capacity
NER-DRC was analyzed as a level of intermediate single-strand breaks (SSBs)
in DNA of (þ)-anti-Benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE)-
treated cells, originated during the incision of BPDE-DNA adducts by NER
pathway. The increase in DNA breaks reflects the ability of NER machinery to
recognize and remove corresponding adducts from DNA.
The methodology is described in detail in Slyskova et al. (29). Briefly,
BPDE was added into the medium with mitogen-stimulated PBMC at
a concentration of 1 lM for 30 min at 37C. After challenge, old medium
was replaced by a new one to remove BPDE excess. PBMC were harvested
immediately after the treatment (time 0) or further cultured and harvested at 1, 2
and 4 h. Separated from medium by centrifugation, cells from each
experimental point were rewashed with PBS and further processed using
a standard comet assay protocol.
In parallel, culturing, harvesting and processing of PBMC of the same
individual and in the same conditions but without any BPDE treatment were
performed. Untreated PBMC represented the basal control DNA damage.
Comet assay
SSBs in DNA were analyzed by the alkaline comet assay based on a routinely
used protocol (30). Experimental conditions for lysis, alkali treatment,
electrophoresis, neutralization and scoring are presented in (29). Data are
reported as tail DNA%, determined in 50 randomly selected cells from two
parallel slides per experimental point.
DRC and endogenous DNA damage calculation
For each experimental point, the net DNA damage value was calculated by
subtracting the basal control tail DNA% of untreated cells from the tail DNA%
of treated cells. Final and reported DRC value was obtained as a difference
between the net level of tail DNA% measured immediately after the treatment
Table II. Characteristics of the study population
Characteristics Category Controlsa CRC patients P-valueb
Sex n 5 70 n 5 70
Female 36 24
Male 34 46 P 5 0.042
Age n 5 70 n 5 70
Mean  standard deviation 62.1  12.7 65.4  10.1
Median (quartiles) 60 (52–74) 66 (58–74)
Range 39–86 39–84 P 5 0.079
Diagnosis n 5 70
Colon 38 (54.3%)
Rectum 32 (45.7%)





Smoking status n 5 69 n 5 66
Non-smokers 54 (78.3%) 50 (75.8%)
Smokers 15 (21.7%) 16 (24.2%) P 5 0.732
Number of cigarettes/day n 5 14 n 5 14
10 9 (64.3%) 6 (42.9%)
.10 5 (35.7%) 8 (57.1%) P 5 0.592
Alcohol consumption n 5 69 n 5 65
No 26 (37.7%) 18 (27.7%)
Yes 43 (62.3%) 47 (72.3%) P 5 0.222
Alcohol intake (grams/day) n 5 43 n 5 43
,25 24 (55.8%) 28 (65.1%)
25–49.9 12 (27.9%) 80 (18.6%)
50–74.9 40 (9.3%) 50 (11.6%)
75–100 3 (7%) 2 (4.7%) P 5 0.342
Body mass index n 5 61 n 5 54
Mean  standard deviation 26.1  4.2 27.5  4.5
,18.5 1 (1.7%) 2 (3.7%)
18.5–24.9 29 (47.5%) 14 (25.9%)
25.0–29.9 24 (39.3%) 23 (42.6%)
30.0–40.0 7 (11.5%) 15 (27.8%) P 5 0.039
Family history of cancer n 5 68 n 5 66
Negative 41 (60.3%) 35 (53%)
Positive 27 (39.7%) 31 (47%) P 5 0.400
CRC in family n 5 61 n 5 63
No 53 (86.9%) 56 (88.9%)
Yes 8 (13.1%) 7 (11.1%) P 5 0.735
Diabetes n 5 66 n 5 65
No 59 (89.4%) 53 (81.5%)
Yes 7 (10.6%) 12 (18.5%) P 5 0.205
aData were not available for all study participants for some parameters.
bOne-way ANOVA for categorical variables, Kruskal–Wallis test for continuous variables. Significant P-values shown in bold.











with BPDE at time 0, and the net value at the maximal increase of tail DNA%
detected up to 4 h of culturing.
The parameter reported as ‘endogenous DNA damage’ represents the mean
value of all independent measurements of tail DNA% of the untreated control
PBMCs.
SSBs in DNA per 109 dalton can be derived from tail DNA% by multiplying
by a conversion factor of 0.042 based on a calibration curve (over the range of
damage detected in the current study, the calibration curve is linear) as reported in
(31).
Expression analysis
RNA isolation and quality control. Total RNA from 2 ml of fresh peripheral
blood sampled into EDTA vacutainers was isolated using TRIzol according to the
procedure supplied by manufacturer (Invitrogen, Paisley, UK) and was kept at
80C. RNA integrity (RIN) was measured using capillary electrophoresis
performed on Agilent Bioanalyzer 2100, with RNA 6000 Nano Assay (Agilent
Technologies, Palo Alto, CA). RIN of all samples were in the range between 8.0
and 10.0. RNA quantity and purity was measured using ASP-3700 Micro-volume
UV/Vis Spectrophotometer (Avans-Biotechnology, Taiwan). OD260/280 ratios for
all samples were between 1.8 and 2.0. Inhibition testing was performed for all
samples by adding internal control template DNA (spike DNA), using Internal
DNA extraction control kit (Primer Design, Southampton, UK) and following
manufacturer’s instructions.
cDNA synthesis and RT-qPCR. Complementary DNA (cDNA) was synthesized
from 1 lg of total RNA by using a RevertAid First strand cDNA synthesis kit
(MBI Fermentas, Vilnius, Lithuania) with random hexamer primers in a final
volume of 40 ll following manufacturer’s instructions. cDNA was stored at
20C. qPCR was performed on 7500 Real Time PCR system (Applied
Biosystems, Foster City, CA) using chemicals produced by Primer Design Ltd.
Precision 2 qPCR Mastermix and custom designed real-time PCR assays with
PerfectProbe were used. All target genes (ERCC1, RAD23B, RPA1, XPA, XPB,
XPC, XPD, XPF, XPG) assays were individually designed and were fully
validated, with guaranteed priming specificity (BLAST screening) and . 90% of
efficiency. Primer sequences are shown in Supplementary Table I, available at
Mutagenesis Online. The PCR reactions were performed in a volume of 20 ll,
containing 25 ng of cDNA for each sample. Cycling program was set at initial
hold at 95C for 10 min, followed by 50 cycles of denaturation at 95C for 15 sec,
annealing and extension at 60C for 32 sec and 72C for 15 sec. Each run
contained positive (interplate calibrator, 25 ng of human cDNA) and negative (no
template) control. Results were analyzed using integrated 7500 System SDS
Software version 1.3.1 (Applied Biosystems).
Reference genes were selected from a geNormTM housekeeping gene
selection kit of 12 genes with PerfectProbeTM and analyzed by both Genorm
and Normfinder algorithms (GenEx Professional, MultiD Analyses AB,
Göteborg, Sweden). Two combinations of selected reference genes (TOP1,
EIF4A2 and B2M, CYC1) were tested for stability in all study samples, but
none of them proved to be a reliable normalization factor, and the same was
observed for total RNA amount. Therefore, Cq values of target genes were
normalized to mean expression of all genes, as it was shown to be the best
normalization factor, applying both Genorm and Normfinder algorithms. M-
value for mean expression of all genes was 0.1, when ignoring groups, or 0.02,
when stratified for groups (patients versus controls). Data are expressed as
relative to maximum quantities (lowest expression was considered as 1).
Expression analyses were performed following MIQE guidelines (11).
Genotyping analysis
Considering the size of our study population, SNPs were chosen according to
the minor allele frequency (MAF . 0.25) and according to the expected effect
on DRC phenotype based on (12). All subjects were genotyped for five
polymorphisms in four NER genes: XPA, XPC, XPD and XPG. For XPD
Lys751Gln (rs28365048), XPG Asn1104His (rs17655) and XPC Lys939Gln
(rs2228001) genotyping a PCR-RFLP procedure was carried out using primers
and conditions previously described (13). For XPC Ala499Val (rs2228000),
primers and conditions of reaction have been described in (15). XPA G23A
(rs1800975) has been analyzed with TaqMan allelic discrimination assay
(Applied Biosystems; Assay-on-demand, SNP genotyping products:
C_482935_1). The results were regularly confirmed by random regenotyping
of .10% of the samples for each polymorphism and showed concordant
results. The genotypes with ambiguous and/or no results were excluded from
the data set. Distribution of genotypes in the study group is shown in
Supplementary Table II, available at Mutagenesis Online.
Statistical analysis
Investigated parameters were normalized by logarithmic transformation due to
their asymmetric distribution in the study population. The relationships
between variables of interest at the bivariate level were studied by means of
T-test, ANOVA and Pearson correlation. The strength of associations between
CRC occurrence and categorical variables at binary level were tested by Chi-
square test. The binary logistic regression was employed to study the
simultaneous association of the DNA damage, NER-DRC and gene expression
with CRC, adjusted for age, sex, smoking habit, alcohol consumption, BMI and
family history of cancer. Genotype frequencies for each polymorphism were
tested for compliance with Hardy–Weinberg equilibrium. All statistical tests
were performed at 5% level of statistical significance; for expression data,
correction for multiple testing analyses (significant P-value after correction
being 0.005) was applied. The SPSS analytical package version 16.0 (Chicago,
IL, USA) was employed for all statistical analyses.
Results
Study population
The study was carried out on 70 incident CRC patients and 70
healthy controls (mean age  SD 65.4  10.1 and 62.1  12.7
years, respectively). In patients, malignancy in colon accounted
for 54.3% of cases, whereas the rest were diagnosed for rectal
cancer. The TNM staging was available for 69 patients: 7 were
classified as stage I, 25 belonged to the stage II, 16 to stage III
and stage IV was assigned for 21 individuals. In one patient,
the pathologist failed to determine TNM. MSI status was
available for 41 cases and 7 out of them (17.1%) were MSI
unstable. The distribution of all clinical, biological or lifestyle
characteristics is reported in Table II. No differences were
observed between patients and controls, except for sex
distribution (males prevailed among patients, P 5 0.042) and
for BMI (lower in controls, P 5 0.039).
Endogenous DNA damage
Significantly higher endogenous DNA damage was observed in
CRC patients, with median 25.9 (interquartile range 4.0–43.0)
tail DNA% as compared to controls, median 9.3 (interquartile
range 2.4–21.5) tail DNA%, (P , 0.001; Figure 1). After
categorizing DNA damage into quartiles, we observed that
incident CRC patients were over-represented in the fourth
quartile category with the highest DNA damage (odds ratio
[OR] 11.49, 95% confidence interval [CI] 3.36–39.34, P ,
0.001), while the controls prevailed among those with the
lowest level of DNA damage (first quartile). Investigated
biological or lifestyle factors (age, sex, smoking status, alcohol
consumption, BMI, family history of cancer and diabetes),
Fig. 1. Endogenous DNA damage level in CRC patients and healthy controls.











when included into the binary logistic regression model, did
not significantly affect the value of regression coefficients.
There was no association between DNA damage and TNM
stage or localization of the tumor.
NER-DRC capacity
The CRC patients, with median 8.7 (interquartile range 2.7–
14.3) tail DNA%, exhibited significantly lower NER-DRC than
the controls with median 12.9 (interquartile range 7.4–20.6) tail
DNA% (P , 0.001; Figure 2a). After categorizing NER-DRC
into quartiles, the subjects with the lowest NER-DRC (the first
quartile) comprised mainly CRC patients, whereas control
subjects were the majority in the fourth quartile with the
highest NER-DRC (OR 0.1, CI 0.03–0.32, P , 0.001). Similar
to DNA damage, none of the investigated biological or lifestyle
factors were associated with NER-DRC and their inclusion into
the binary logistic model did not affect the value of regression
coefficient. DNA damage and NER-DRC did not significantly
correlate, either in the pooled study population or according to
the diagnosis. Despite only a moderate decrease of NER-DRC
in patients with TNM from I to III, a most pronounced
reduction in NER-DRC was observed in patients with stage IV
(P 5 0.036, Figure 2b).
Expression and genotyping analyses
Expression profile was analyzed in a subgroup of 66 patients
and 42 controls, for which RNA material was available and
which pass the selection criteria for RNA purity and quality
and control of PCR inhibition (as described in Materials and
methods). Out of nine studied genes, mRNA levels of six of
them significantly differed between patients and controls, also
after applying correction for multiple testing analysis (signif-
icant P-value after correction being 0.005). Expression levels
of XPB and XPF genes were higher in control group, while
higher expression levels of XPA, XPG, ERCC1 and RAD23B
were detected in patients (for all P  0.001, Figure 3). A strong
relationship between expression levels of RAD23B, XPG and
ERCC1 genes was observed in the whole study group (R 5
0.98, P , 0.001) and after stratification for patients and
controls. Expression levels of any studied repair gene did not
correlate with DNA damage or DRC and were not modulated
by any of clinical, biological or lifestyle factors.
Distribution of the analyzed genotypes was in agreement
with the Hardy–Weinberg equilibrium. None of the studied
Fig. 2. (a) NER-DRC in CRC patients and healthy controls. (b) NER-DRC in
CRC patients stratified according to TNM staging.
Fig. 3. mRNA expression levels of nine NER genes in CRC patients and healthy controls, expressed as quantities relative to the lowest detected expression assigned
as value 1.











SNPs were significantly associated with DNA damage levels or
DRC, either in patients or in controls. Expression levels were
only moderately modulated by some SNPs. In cases only,
variant allele of XPC Ala499Val was associated with lower
XPC and higher XPB and XPD expression levels (for all P ,
0.05). In controls, variant allele of XPC Lys939Gln was
associated with higher XPA expression level (P , 0.05; data
not shown).
Discussion
DRC reflects the actual capacity of the organism to maintain
DNA integrity and constitutes an informative biomarker of
intermediate cancer phenotype (19). Our study represents an
investigation on basal DNA damage and DRC in relation to
sporadic CRC. In particular, we have focused our interest on
evaluation of individual DRC characterizing NER activity. To
approach this, we have challenged PBMC of study subjects by
BPDE and quantified the removal of BPDE adducts from DNA
(which reflects rate-limiting incision step of NER pathway) by
a modified version of comet assay. BPDE was chosen as a model
compound for two main reasons. First, it is a metabolite of
carcinogen benzo(a)pyrene (BaP), to which an organism is
commonly exposed from various sources. Along with environ-
mental or occupational pollution, BaP is generated also by
pyrosynthesis in burning tobacco or in meat prepared at high
temperatures. Second, BPDE binds to DNA, forming pre-
dominantly N2-deoxyguanosine bulky adducts, which have been
detected in colonic mucosa (20) and are specifically removed by
NER (16). Generally, NER recognizes a wide spectrum of bulky
DNA lesions induced by UV light and a variety of helix-
distorting agents (17). A reduced NER capacity may conse-
quently enhance the CRC risk due to a diminished protection of
intestinal epithelium against genotoxic compounds, present in
the lumen or transported by the blood.
In our study group, newly diagnosed CRC patients had
significantly lower NER-DRC and higher levels of SSBs in
DNA as compared to the age-matched healthy subjects. This
was clearly documented after categorization of the above param-
eters into quartiles, where accumulation of SSBs and decreasing
DRC were characteristic for CRC patients. Interestingly, the two
parameters behaved as factors independently associated with
sporadic CRC. Furthermore, when the cases were stratified
according to the TNM staging, significantly lower NER-DRC
was observed in patients with the stage IV in comparison to
those with less severe/invasive stages of the disease. A gradual
decrease of DRC with increasing TNM stage in a surrogate
tissue possibly reflects important biological phenomenon in
relation to progression of the disease. Deficient or reduced NER-
DRC was already reported as a risk factor for several different
cancers, including bladder (18), breast (21,22), skin (23–25),
head and neck (14,32,33), lung (34–37) and prostate cancer (38),
as summarized in Table I. Our results contribute to the list of
evidences on the importance of NER-DRC in carcinogenesis,
showing the same relevance also for sporadic CRC. To our
knowledge, the only study investigating specifically NER
capacity in sporadic CRC patients was performed almost 30
years ago by unscheduled DNA synthesis in smaller study group
(39).
Simultaneously with reduced NER-DRC, CRC patients
exhibited elevated endogenous DNA damage. The arbitrary unit
of tail DNA% may be converted to SSBs/106 nucleotides
(31,40). By expressing our data in this latter unit, we obtain 0.18
versus 0.37 SSBs/106 nucleotides in studied controls and
patients, respectively which means 540 versus 1113 breaks/
cell. Pooling together data from 119 publications reporting
endogenous DNA damage extent in cancer-free populations (41),
a clear positive correlation was observed between level of SSBs
and age. For individuals belonging to the 50- to 64-year-old
group, an average SSB level of 510 breaks/cell was calculated,
which is in full agreement with our data. This demonstrates that
CRC patients bear .2-fold higher level of strand breaks in DNA
than the reference value for healthy population of the same age.
The enhanced levels of DNA damage represent an additional
suggestion for a generally altered status of the DNA repair
machinery among cancer patients. In agreement with our
findings, several studies have shown that basal DNA damage
is indeed increased in leukocytes of patients suffering from
a variety of different forms of cancer, as reviewed by (42). On
the other hand, we cannot rule out that the level of endogenous
DNA damage may comprise various alkali-labile DNA lesions,
converted during comet assay into SSBs. These lesions are
a target for BER pathway, which was also reported to be
deficient in cancer patients (43,44).
Additionally, mRNA quantity of nine genes involved in the
recognition/incision step of NER was studied. Expression
levels of individual genes were not significantly related to
either NER-DRC or the extent of DNA damage. However,
a coordinated expression of RAD23B, XPG and ERCC1 genes
was observed. This is an interesting finding considering that
XPC-RAD23B complex acts in DNA damage recognition and
subsequently recruits the XPG and ERCC1/XPF to the site of
damage directly or via strong interactions with TFIIH nine
subunits complex (45,46). Six NER genes were found to be
differently transcribed between patients and controls. XPB and
XPF had higher expression in controls, while XPA, XPG,
ERCC1 and RAD23B were more expressed in patients. Such
a finding is somehow surprising, as total DRC was shown to be
lower in patients. Observed expression profiles and the lack of
correlation between quantity of mRNA and DRC may be in
concordance with previous observations showing that mRNA
quantity does not necessarily reflect the activity of protein
(47,48) or overall repair capacity (49,50). In some cases, it is
the absence rather than the relative content of a functional
protein that is important for cellular activity. Moreover, genes
act in interactive networks and alterations of each of them
might have different impact on the overall cell function (51).
Communication between the NER system and DNA damage
signaling may also play a critical role (52).
In the present study, we have also attempted to relate
outcomes of functional tests and expression levels to relevant
variation in some NER genes. The individual differences in
DNA damage levels and DRC as well as expression levels have
been hypothesized for many years to be associated to
individual genetic background in DNA repair genes (13,29).
In our hands, investigated SNPs were not significantly
associated with either DNA damage or DRC after stratification
for health status. However, there were some associations with
NER gene expression, the most interesting being a modulation
of expression levels of XPC, XPB and XPD by XPC Ala499Val
variant allele in CRC patients. A potential functional effect of
this SNP is supported by previous studies on susceptibility to
cancer (53,54). A role of SNPs in NER pathway on sporadic
CRC risk has been recently postulated (55,56), but the limited
size of our currently studied population precludes evaluation of
the association of individual SNPs with CRC risk. The actual











association of variation in DNA repair genes and CRC risk has
not been clearly disclosed either in the context of recent
genome-wide association studies (57).
In conclusion, our study provides evidence on alterations of
cellular DRC among sporadic CRC patients and suggests the
role of NER in its etiology. However, one of the main future
challenges with intermediate biomarkers, like DNA damage
and DRC, is to understand whether they belong to the causal
pathway of a disease, whether they are simply a side effect of
a disease or whether their measurement may be confounded by
some other factors.
Genes involved in DNA damage recognition/incision phase
of NER act in an interplay and in a synchronized way (45,58).
Based on our findings, this process is more comprehensively
characterized by functional quantification of repair capacity
than by quantification of individual gene transcripts or gene
variants. Overall, our observation points out the usefulness of
DRC analyses, which measure the real outcome of a complex
multigene process, as also recently concluded by Collins and
Azqueta (59). Comet assay is a convenient methodology for
DRC evaluation and high-throughput versions of it are
currently under development. This will allow the simultaneous
determination of DRC in multiple samples and thus making
this assay suitable for large population screening minimizing
inter-experimental variation (60).
Supplementary data
Supplementary Tables I and II are available at Mutagenesis
Online.
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